NanoString Technologies Inc. (NSTG) Jumps 5.31% on February 17

Equities Staff |

NanoString Technologies Inc. (NSTG) was among the biggest gainers on the Russell 2000 for Wednesday February 17 as the stock popped 5.31% to $12.69, representing a gain of $0.64 per share. Some 164,173 shares traded hands on 943 trades, compared with an average daily volume of 131,623 shares out of a total float of 19.51 million. The stock opened at $12.23 and traded with an intraday range of $12.81 to $11.97.

After today's gains, NanoString Technologies Inc. reached a market cap of $247.54 million. NanoString Technologies Inc. has had a trading range between $19.81 and $9.95 over the last year, and it had a 50-day SMA of $13.87 and a 200-day SMA of $14.71.

NanoString Technologies Inc develops, manufactures and sells products that unlock scientifically valuable and clinically actionable genomic information from minute amounts of tissue.

NanoString Technologies Inc. is based out of Seattle, WA and has some 276 employees. Its CEO is R. Bradley Gray.

For a complete fundamental analysis analysis of NanoString Technologies Inc., check out Equities.com’s Stock Valuation Analysis report for NSTG. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Mesa-Marshall 2 Well Project

MESA Resources ("MESA") is sponsoring the development of the two well direct drilling project -- "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development of…

Trustify

Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…